See more : Eclat Textile Co., Ltd. (1476.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Arctic Bioscience AS (ABS.OL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arctic Bioscience AS, a leading company in the Biotechnology industry within the Healthcare sector.
- LaserBond Limited (LBL.AX) Income Statement Analysis – Financial Results
- Eco-Tek Group, Inc. (ETEK) Income Statement Analysis – Financial Results
- Sing Tao News Corporation Limited (STAOF) Income Statement Analysis – Financial Results
- African Agriculture Holdings Inc. (AAGRW) Income Statement Analysis – Financial Results
- KWESST Micro Systems Inc. (KWE) Income Statement Analysis – Financial Results
Arctic Bioscience AS (ABS.OL)
About Arctic Bioscience AS
Arctic Bioscience AS, a biotechnology company, develops and commercializes pharmaceutical and nutraceutical products. Its development stage product candidate is HRO350, a novel oral treatment for mild-to-moderate psoriasis. The company sells its nutraceuticals as bulk ingredients to other companies under the ROMEGA brand worldwide. Arctic Bioscience AS was incorporated in 2011 and is based in Ørsta, Norway.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 33.75M | 34.27M | 21.52M | 20.50M | 30.04M | 24.85M |
| Cost of Revenue | 23.98M | 22.63M | 16.36M | 15.18M | 17.81M | 15.90M |
| Gross Profit | 9.77M | 11.65M | 5.16M | 5.31M | 12.23M | 8.95M |
| Gross Profit Ratio | 28.96% | 33.98% | 23.98% | 25.93% | 40.73% | 36.02% |
| Research & Development | 2.59M | 0.00 | 0.00 | 0.00 | 111.09K | 197.02K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | -2.58M | 0.00 | 0.00 | 0.00 | 8.57M | 3.10M |
| Other Expenses | 58.36M | 197.10K | 400.00 | 96.12K | 0.00 | -130.58K |
| Operating Expenses | 58.37M | 49.04M | 45.74M | 26.02M | 15.32M | 10.10M |
| Cost & Expenses | 82.34M | 71.66M | 62.09M | 41.20M | 33.12M | 26.00M |
| Interest Income | 3.74M | 1.89M | 118.58K | 18.39K | 47.75K | 9.25K |
| Interest Expense | 992.62K | 1.25K | 342.03K | 509.63K | 469.17K | 519.59K |
| Depreciation & Amortization | 5.38M | 3.73M | 2.52M | 224.42K | 1.08M | 526.52K |
| EBITDA | -37.78M | -30.29M | -37.94M | -20.89M | -2.33M | -663.83K |
| EBITDA Ratio | -111.95% | -88.39% | -184.61% | -97.19% | -8.13% | -2.67% |
| Operating Income | -48.59M | -37.39M | 40.58M | -21.67M | -3.08M | -1.15M |
| Operating Income Ratio | -143.96% | -109.10% | 188.60% | -105.75% | -10.26% | -4.63% |
| Total Other Income/Expenses | 3.07M | 3.36M | -2.00M | -915.94K | -906.42K | -560.20K |
| Income Before Tax | -45.51M | -34.02M | -42.58M | -22.59M | -3.99M | -1.71M |
| Income Before Tax Ratio | -134.86% | -99.28% | -197.91% | -110.21% | -13.28% | -6.88% |
| Income Tax Expense | 0.00 | 3.37M | -82.82M | 561.23K | -437.26K | -40.60K |
| Net Income | -45.51M | -34.02M | -42.58M | -22.59M | -3.99M | -1.71M |
| Net Income Ratio | -134.86% | -99.28% | -197.91% | -110.21% | -13.28% | -6.88% |
| EPS | -1.79 | -1.40 | -1.75 | -0.93 | -0.16 | -0.07 |
| EPS Diluted | -1.79 | -1.40 | -1.75 | -0.93 | -0.16 | -0.07 |
| Weighted Avg Shares Out | 25.43M | 24.38M | 24.30M | 24.30M | 24.30M | 24.30M |
| Weighted Avg Shares Out (Dil) | 25.43M | 24.38M | 24.30M | 24.30M | 24.30M | 24.30M |
Source: https://incomestatements.info
Category: Stock Reports